

**05-06-2015**

<b>11:00 - 11:15</b>	<b>Official welcome to the Pre-IMPAKT Training Course 2015</b> Chair: C. Desmedt, BE; P. Schmid, UK	<b>The Arc</b>
11:00 - 11:15	<b>Welcome to the Pre-IMPAKT Training Course 2015</b> <u>C. Desmedt</u> <sup>1</sup> , <u>P. Schmid</u> <sup>2</sup> ; <sup>1</sup> BE, <sup>2</sup> UK	
<b>11:15 - 12:55</b>	<b>Basics in cancer biology</b> Chair: K. Willard-Gallo, BE	<b>The Arc</b>
11:15 - 11:35	<b>Cell cycle</b> <u>E. Knudsen</u> , TX/US	
11:35 - 11:40	<b>Q&amp;A</b>	
11:40 - 12:00	<b>DNA repair</b> <u>J. Feunteun</u> , FR	
12:00 - 12:05	<b>Q&amp;A</b>	
12:05 - 12:25	<b>Cancer epigenetics</b> <u>F. Fuks</u> , BE	
12:25 - 12:30	<b>Q&amp;A</b>	
12:30 - 12:50	<b>Cancer immunology</b> <u>K. Willard-Gallo</u> , BE	
12:50 - 12:55	<b>Q&amp;A</b>	
<b>12:55 - 13:45</b>	<b>Lunch</b>	<b>The Arc Foyer</b>



<b>13:45 - 15:25</b>	<b>Tools, tips and tricks for biomarker research</b> Chair: C. Denkert, DE	<b>The Arc</b>
13:45 - 14:05	<b>Sample collection and processing</b> <u>C. Denkert</u> , DE	
14:05 - 14:10	<b>Q&amp;A</b>	
14:10 - 14:30	<b>Validated assays in pathology</b> <u>I. Migliaccio</u> , IT	
14:30 - 14:35	<b>Q&amp;A</b>	
14:35 - 14:55	<b>Quantification and qualification of immune infiltrates: International standardisation</b> <u>R. Salgado</u> , BE	
14:55 - 15:00	<b>Q&amp;A</b>	
15:00 - 15:20	<b>Introduction to proteomics</b> <u>M. Ellis</u> , TX/US	
15:20 - 15:25	<b>Q&amp;A</b>	
<b>15:25 - 15:45</b>	<b>Coffee break</b>	<b>The Arc Foyer</b>



<b>15:45 - 17:00</b>	<b>Rapidly evolving research areas</b> Chair: J. Reis-Filho, US	<b>The Arc</b>
15:45 - 16:05	<b>Introduction to Next Generation Sequencing</b> <u>S. Nik-Zainal</u> , UK	
16:05 - 16:10	<b>Q&amp;A</b>	
16:10 - 16:30	<b>How to use genomics in paraffin samples</b> <u>J. Reis-Filho</u> , NY/US	
16:30 - 16:35	<b>Q&amp;A</b>	
16:35 - 16:55	<b>Interrogating liquid biopsies: Tools, promises and challenges</b> <u>D. Tsui</u> , UK	
16:55 - 17:00	<b>Q&amp;A</b>	
<b>17:00 - 17:45</b>	<b>Resources for translational research</b> Chair: F. André, FR	<b>The Arc</b>
17:00 - 17:15	<b>Public dataset and tools</b> <u>C. Desmedt</u> , BE	
17:15 - 17:20	<b>Q&amp;A</b>	
17:20 - 17:40	<b>How to write successful grants in translational research</b> <u>F. André</u> , FR	
17:40 - 17:45	<b>Q&amp;A</b>	
<b>17:45 - 18:30</b>	<b>Training Course cocktail</b>	<b>The Arc Foyer</b>

05-07-2015



<b>09:00 - 10:15</b>	<b>Basic in statistics and clinical trial design</b> Chair: S. Michiels, FR	<b>The Arc</b>
09:00 - 09:20	<b>Basics in statistical tests</b> <u>E. Biganzoli</u> , IT	
09:20 - 09:25	<b>Q&amp;A</b>	
09:25 - 09:45	<b>How to report translational research results</b> <u>S. Michiels</u> , FR	
09:45 - 09:50	<b>Q&amp;A</b>	
09:50 - 10:10	<b>Basics in clinical trial design</b> <u>M. Arnedos</u> , FR	
10:10 - 10:15	<b>Q&amp;A</b>	
<b>10:15 - 10:45</b>	<b>Coffee break</b>	<b>The Arc Foyer</b>
<b>10:45 - 11:35</b>	<b>Translation from biomarker to the clinic</b> Chair: P. Schmid, UK	<b>The Arc</b>
10:45 - 11:05	<b>Early drug development</b> <u>P. Schmid</u> , UK	
11:05 - 11:10	<b>Q&amp;A</b>	
11:10 - 11:30	<b>Target validation</b> <u>N. Turner</u> , UK	
11:30 - 11:35	<b>Q&amp;A</b>	
<b>11:35 - 13:00</b>	<b>Training course lunch</b>	<b>The Arc Foyer</b>



<b>13:00 - 13:15</b>	<b>Official welcome</b>	<b>Gold Hall</b>
	Chair: N. Turner, UK; M. Piccart, BE; C. Denkert, DE	
13:00 - 13:05	<b>Welcome to the IMPAKT Conference</b> <u>M. Piccart</u> , BE	
13:05 - 13:15	<b>Introduction to the IMPAKT Conference</b> <u>C. Denkert</u> <sup>1</sup> , <u>N. Turner</u> <sup>2</sup> ; <sup>1</sup> DE, <sup>2</sup> UK	
<b>13:15 - 14:15</b>	<b>Opening Keynote session</b>	<b>Gold Hall</b>
	Chair: S. Chandarlapaty, US; C. Sotiriou, BE	
13:15 - 13:45	<b>Tracing the cellular origin of breast cancer</b> <u>C. Blanpain</u> , BE	
13:45 - 14:05	<b>Concepts on cells of origin of cancer: Implications for clinical practice</b> <u>L. Norton</u> , NY/US	
14:05 - 14:15	<b>Q&amp;A</b>	
<b>14:15 - 15:45</b>	<b>The molecular origin of breast cancer: Clinical significance of genomic patterns</b>	<b>Gold Hall</b>
	Chair: A.M. Thompson, US; J. Reis-Filho, US	
14:15 - 14:35	<b>Genomic ventures to explore tumour development and intra-tumour heterogeneity in breast cancer</b> <u>P. Van Looy</u> , UK	
14:35 - 14:55	<b>APOBEC mutation signatures and the origins of mutation in breast cancer</b> <u>R. Harris</u> , MN/US	
14:55 - 15:10	<b>Which mutations are relevant? Strategies for identification</b> <u>S. Nik-Zainal</u> , UK	
15:10 - 15:25	<b>Therapeutic implications of mutational evolution in breast cancer</b> <u>L. Pusztai</u> , CT/US	
15:25 - 15:45	<b>Q&amp;A / General Discussion</b>	
<b>15:45 - 16:15</b>	<b>Coffee break</b>	<b>Delvaux Foyer</b>



<b>16:15 - 17:45</b>	<b>Best abstracts session</b>	<b>Gold Hall</b>
	Chair: N. Turner, UK; C. Denkert, DE	
16:15 - 16:25	<b>390 - Constitutively activated STAT3 is predictive for trastuzumab resistance in primary HER2 positive breast cancer</b> <u>A. Sonnenblick</u> <sup>1</sup> , S. Brohée <sup>1</sup> , R. Salgado <sup>1</sup> , G. Van den Eynden <sup>1</sup> , P. Neven <sup>1</sup> , S. Loibl <sup>2</sup> , C. Denkert <sup>2</sup> , H. Joensuu <sup>3</sup> , M. Piccart <sup>1</sup> , C. Sotiriou <sup>1</sup> ; <sup>1</sup> BE, <sup>2</sup> DE, <sup>3</sup> FI	
16:25 - 16:35	<b>860 - PI3 kinase/mTOR inhibition increases sensitivity of ER positive breast cancers to CDK4/6 inhibition by blocking cell cycle re-entry driven by cyclinD1 and inducing apoptosis</b> <u>M.T. Herrera-Abreu</u> <sup>1</sup> , U. Asghar <sup>1</sup> , R. Elliot <sup>1</sup> , A. Pearson <sup>1</sup> , M. Nannini <sup>2</sup> , A. Young <sup>2</sup> , D. Sampath <sup>2</sup> , M. Dowsett <sup>1</sup> , L. Martin <sup>1</sup> , N. Turner <sup>1</sup> ; <sup>1</sup> UK, <sup>2</sup> CA/US	
16:35 - 16:45	<b>400 - Identification of gene expression signatures of palbociclib (PD) response in breast cancer (BC)</b> <u>I. Migliaccio</u> , S. Piazza, R. Verardo, C. Guarducci, M. Bonechi, Y. Ciani, E. Moretti, O. Siclari, A. Di Leo, L. Malorni; IT	
16:45 - 17:00	<b>Invited Discussant</b> <u>L. Carey</u> , NC/US	
17:00 - 17:10	<b>230 - Clinical patterns of metastatic spread from formalin-fixed, paraffin-embedded (FFPE) expression profiles: A case-control study of 1,357 breast cancer patients</b> <u>K. Lawler</u> , E. Papouli, A. Tutt, T. Ng, S. Pinder, P. Parker, L. Holmberg, C. Gillett, A. Grigoriadis, A. Purushotham; UK	
17:10 - 17:20	<b>410 - Exploring the intra-patient PIK3CA mutational heterogeneity of circulating tumour cells by massive parallel sequencing in patients with metastatic hormone receptor-positive breast cancer</b> <u>B. De Laere</u> , D. Peeters, R. Salgado, P. Vermeulen, P. van Dam, L. Dirix, S. Van Laere; BE	
17:20 - 17:30	<b>420 - Profiles of genome complexity identify HORMAD1 as a driver of homologous recombination deficiency and platinum therapy response in triple-negative breast cancer</b> <u>A. Grigoriadis</u> <sup>1</sup> , D. Weekes <sup>1</sup> , J. Watkins <sup>1</sup> , P. Gazinska <sup>1</sup> , J. Frankum <sup>1</sup> , C. Lord <sup>1</sup> , A. Ashworth <sup>1</sup> , J. Ford <sup>2</sup> , M. Telli <sup>2</sup> , A. Tutt <sup>1</sup> ; <sup>1</sup> UK, <sup>2</sup> CA/US	
17:30 - 17:45	<b>Invited Discussant</b> <u>F. Symmans</u> , TX/US	
<b>17:45 - 19:00</b>	<b>Welcome reception and Poster Walk</b>	<b>Delvaux Foyer</b>
17:45 - 17:45	<b>EARLY BREAST CANCER SYSTEMIC THERAPY</b>	
17:45 - 17:45	<b>1P - A phase III randomized study of paclitaxel and trastuzumab versus paclitaxel alone for early stage, ER and PR receptor negative and HER2-positive breast cancer as adjuvant treatment</b> <u>M. Singhal</u> , A. Kapoor, S. Narayan, S. Maharia, R. Nirban, S. Beniwal, H. Kumar; IN	
17:45 - 17:45	<b>2P - Agreement in risk assessment among breast cancer specialists: A survey within the MINDACT cohort</b> <u>C. Drukker</u> <sup>1</sup> , L. Slaets <sup>2</sup> , R. Goossens <sup>2</sup> , M. Schmidt <sup>1</sup> , E. Rutgers <sup>1</sup> , F. Cardoso <sup>3</sup> , S. Linn <sup>1</sup> , J. Bogaerts <sup>2</sup> ; <sup>1</sup> NL, <sup>2</sup> BE, <sup>3</sup> PT	



- 17:45 - 17:45 **3P - Estimated number of Korean women who could benefit from tamoxifen or raloxifene for breast cancer chemoprevention: data from the Korea National Health and Nutrition Examination Survey**  
M.-C. Chang, J.W. Min; KR
- 17:45 - 17:45 **4P - Influence of anthracycline- and/or taxane-based chemotherapy on bone metabolism of patients with primary breast cancer**  
C. Kurbacher, N. Rauschenbach, A. Kurbacher, S. Herz, K. Monreal, C. Bartling, J. Kurbacher, A. Quade; DE
- 17:45 - 17:45 **5P - Lipid profiles of young Chinese breast cancer after adjuvant chemotherapy**  
W. Yeo, C. Yip, F. Mo, E. Pang, C. Yip, K. Lee, V. Chan, J. Suen, W. Ho, T. Liem; HK
- 17:45 - 17:45 **6P - Pregnancy-associated breast cancer: Influence of gestation length and breastfeeding on survival in a population based cohort**  
J. Mackie<sup>1</sup>, A. Ives<sup>2</sup>, M. Bulsara<sup>2</sup>, C. Saunders<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>WA/AU
- 17:45 - 17:45 **7P - Breast cancer awareness and early detection practices among Omani women: A cross-sectional survey**  
E. Al-Khasawneh, V. Seshan, Y. Al-Farsi, S. Siddiqui, M. Al-Moundhri; OM
- 17:45 - 17:45 **8P - Effect of long term yoga practice on psychological and immune outcomes in breast cancer survivors**  
A. Ram<sup>1</sup>, N. Raghuram<sup>1</sup>, R. Rao<sup>1</sup>, V. Veldore<sup>1</sup>, M.R. Usharani<sup>1</sup>, G. Kodaganur<sup>1</sup>, B.S. Ajaikumar<sup>1</sup>, S. Reddy<sup>2</sup>; <sup>1</sup>IN, <sup>2</sup>CA/US
- 17:45 - 17:45 **LOCO-REGIONAL THERAPY**
- 17:45 - 17:45 **9P - ZOO 11 trial: Does it influence our clinical practice in the United Kingdom**  
A. Syed, W. Nabi, J. Lawrence, S.R. Eleti, E. Gray; UK
- 17:45 - 17:45 **10P - Radiotherapy plus trastuzumab in the treatment of Her2-positive locally advanced breast cancer**  
A. Belokhvostova, Y. Ragulin; RU
- 17:45 - 17:45 **11P - 10-year results of complex treatment with reactor neutrons in locally advanced breast cancer (BC)**  
Y. Ragulin, Y. Mardynsky, I. Gulidov, G. Aminov, V. Medvedev, A. Sysoev, I. Kotuchov; RU
- 17:45 - 17:45 **12P - Outcome analysis of patients with breast cancer and positive sentinel node**  
A. Syed, S.R. Eleti, R. Buhain; UK
- 17:45 - 17:45 **ADVANCED BREAST CANCER SYSTEMIC THERAPY**
- 17:45 - 17:45 **13P - Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR&plus; triple-negative breast cancer (TNBC)**  
J. Cortes Castan<sup>1</sup>, P. Schmid<sup>2</sup>, A. Awada<sup>3</sup>, H. Uppal<sup>4</sup>, I.C. Tudor<sup>4</sup>, M. Blaney<sup>5</sup>, J. Steinberg<sup>6</sup>, D. Yardley<sup>7</sup>, C. Hudis<sup>8</sup>, T. Traina<sup>8</sup>; <sup>1</sup>ES, <sup>2</sup>UK, <sup>3</sup>BE, <sup>4</sup>CA/US, <sup>5</sup>US, <sup>6</sup>IL/US, <sup>7</sup>TN/US, <sup>8</sup>NY/US



- 17:45 - 17:45 **14P - KEYNOTE-012: A phase Ib study of pembrolizumab (MK-3475) in patients (pts) with metastatic triple-negative breast cancer (mTNBC)**  
L. Buisseret<sup>1</sup>, J. Specht<sup>2</sup>, E..C. Dees<sup>3</sup>, R. Berger<sup>4</sup>, S. Gupta<sup>5</sup>, R. Geva<sup>4</sup>, L. Pusztai<sup>6</sup>, C. Gause<sup>7</sup>, V. Karantza<sup>7</sup>, R. Nanda<sup>8</sup>; <sup>1</sup>BE, <sup>2</sup>WA/US, <sup>3</sup>NC/US, <sup>4</sup>IL, <sup>5</sup>US, <sup>6</sup>CT/US, <sup>7</sup>NJ/US, <sup>8</sup>IL/US
- 17:45 - 17:45 **15P - Transarterial chemoembolization with doxorubicin-loaded drug-eluting beads (DEBDOX) in the treatment of breast cancer liver metastases: A pilot study**  
G. Bruixola, R. García, F. Gomez, C. Escóin, L. Palomar, H. de la Cueva, J. Martínez, A. Santaballa; ES
- 17:45 - 17:45 **16P - Comparison of bevacizumab &plus; chemotherapy regimens for triple-negative type locally advanced breast cancer**  
A. Kenjaeva, Z. Olimova, E. Gafurov; UZ
- 17:45 - 17:45 **17P - Intravenous thiotepa for treatment of leptomeningeal carcinomatosis: Retrospective case series**  
J. Chahal, P. Chalasani, A. Stopeck, K. Clarke, R. Livingston; AZ/US
- 17:45 - 17:45 **18P - Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Multicentric, retrospective and prospective collection of patient data and biomaterial from breast cancer patients as platform for translational research**  
V. Müller, E. Laakmann, T. Fehm, V. Möbus, G. von Minckwitz, J. Kaiser, S. Loibl, I. Witzel; DE
- 17:45 - 17:45 **19P - High reduction of circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin)**  
L. Manso, F. Moreno, J.I. Delgado, M.J. Echarri, A. López, Y. Izarzugaza, P. Borrega, N. Martínez, C. Olier, H. Cortes-Funes; ES
- 17:45 - 17:45 **20P - Targeting HER2 in patients with HER2-negative metastatic breast cancer with elevated serum levels of the HER2 extracellular domain and/or HER2-positive circulating tumor cells in the clinical routine**  
C. Kurbacher, A. Quade, G. Kunstmann, S. Herz, J. Kurbacher, M. Warm; DE
- 17:45 - 17:45 **21P - Expression of CD138 / syndecan-1 in triple-negative breast cancer – correlative study of GeparSixto**  
G. von Minckwitz, B. Pfitzner, V. Müller, P. Fasching, T. Karn, C. Schem, K. Schönfeld, T. Häder, S. Loibl, C. Denkert; DE
- 17:45 - 17:45 **22P - Can pathological complete response serve as a surrogate endpoint for survival?**  
N. Hariharan, N. Nair, V. Parmar, R. Hawaldar, P. Padmanaban, V. Vanmali, R. Badwe; IN
- 17:45 - 17:45 **GENOMICS AND PROTEOMIC ANALYSIS OF BREAST CANCER**
- 17:45 - 17:45 **24P - Phosphoproteomic assessment of HER2 signaling pathway in HER2 non-amplified patients of the GeparQuattro and GeparQuinto trials**  
S. Avril<sup>1</sup>, G. von Minckwitz<sup>2</sup>, K. Malinowsky<sup>2</sup>, P. Fasching<sup>2</sup>, T. Karn<sup>2</sup>, A. Hartmann<sup>2</sup>, M. Untch<sup>2</sup>, C. Denkert<sup>2</sup>, K.-F. Becker<sup>2</sup>, S. Loibl<sup>2</sup>; <sup>1</sup>OH/US, <sup>2</sup>DE
- 17:45 - 17:45 **25P - Detection of HER2-status and genomic analysis of disseminated cancer cells (DCCs) of non-metastatic breast cancer patients with HER2-negative and positive primary tumors**  
E. Doblinger, O. Schmidt, Z. Czyz, G. Haunschild, B. Rack, T. Schamberger, C. Klein; DE



- 17:45 - 17:45 **26P - Whole exome sequencing of circulating and disseminated tumour cells in patients with metastatic breast cancer**  
D. Peeters, A. Brouwer, K. Op de Beeck, G. Van de Weyer, P. Pauwels, M. Peeters, P. Vermeulen, S. Van Laere, G. Van Camp, L. Dirix; BE
- 17:45 - 17:45 **27P - Common gene signature expressed by breast and kidney cancers-derived endothelial colony forming cells**  
R. Tancredi, V. Fotia, F. Moccia, V. Rosti, C. Porta, M.G. Della Porta, L. Beltrame, A. Zambelli, G.A. Da Prada, A. Riccardi; IT
- 17:45 - 17:45 **28P - Germ cells and mammary gland transcriptome comparison generate a powerful gene expression profile that predicts breast cancer survival**  
D. Tiezzi, H. Noushmehr, W. Silveira, T. Sabedot, J. Andrade; BR
- 17:45 - 17:45 **29P - Effect of delays in time to fixation due to routine X-ray of surgical breast cancer specimens on gene expression profiles**  
E. Lopez Knowles, A. Gao, F. Macneill, I. Pinhel, L. Martin, M. Dowsett; UK
- 17:45 - 17:45 **30P - Differential microRNA expression in breast cancer patients aged 35 years or younger**  
G. Ribas, M. Peña-Chilet, S. Oltra, M.T. Martinez, A. Lluch-Hernandez, G. Ayala; ES
- 17:45 - 17:45 **31P - Multigene sequencing for the genetic diagnostics of patients with early-onset or familial breast cancer**  
P.-H. Lin, W.-H. Kuo, C.-H. Lin, Y.-S. Lu, Y.-H. Ni, C.-S. Huang; TW
- 17:45 - 17:45 **32P - Molecular characterization of breast cancer brain metastases and circulating tumor cells**  
H. Wikman, I. Hohensee, C. Riebensahm, I. Witzel, J. Matschke, M. Glatzel, K. Lamszus, S. Riehdorf, V. Müller, K. Pantel; DE
- 17:45 - 17:45 **33P - Genetic study of triple negative breast cancers**  
M. Boukerroucha, C. Josse, S. ElGuendi, P. Freres, R. Marée, S. Wenric, K. Segers, J. Collignon, G. Jerusalem, V. Bours; BE
- 17:45 - 17:45 **34P - The GATA3 and SENP5 network demonstrates control over breast cancer phenotypes**  
S. Efroni, R. Ben-Hamo; IL
- 17:45 - 17:45 **35P - MiR-16 is the most stable-expressed housekeeping microRNA in breast cancer tissues from primary and metastatic sites**  
G. Rinnerthaler, H. Hackl, F. Hamacher, S.P. Gampenrieder, C. Hufnagl, F. Romeder, C. Monzo Fuentes, C. Hauser-Kronberger, B. Mlineritsch, R. Greil; AT
- 17:45 - 17:45 **36P - Incidence of oncogenes in PI3K/AKT and MAPK signaling pathways in breast cancer**  
J.M. Cejalvo, J.A. Perez Fidalgo, B. Bermejo, M. Ibarrola-Villaba, O. Burgues, G. Ribas, M.T. Martinez, A. Lluch-Hernandez; ES
- 17:45 - 17:45 **37P - P14ARF-p53-p21 alters the metabolic pathway in breast cancer – a novel proteomic global approach**  
D. Hatoum<sup>1</sup>, D. Yagoub<sup>2</sup>, S. Brennan<sup>2</sup>, N. Nassif<sup>2</sup>, E. McGowan<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>NSW/AU
- 17:45 - 17:45 **38P - Retinoic acid signaling in human breast cancer cells: A phosphoproteomic approach**  
M. Carrier, M. Joint, R. Lutzing, A. Page, C. Rochette-Egly; FR
- 17:45 - 17:45 **BIOMARKERS IN BREAST CANCER (PROGNOSTIC, PREDICTIVE AND PHARMACODYNAMIC)**



- 17:45 - 17:45 **43P - Development and validation of multiplex digital PCR assays on circulating tumor DNA in advanced breast cancer: Implementation for clinical routine use**  
I. Garcia-Murillas, G. Schiavon, S. Hrebien, B. O'Leary, J. Morden, I. Smith, N. Turner; UK
- 17:45 - 17:45 **44P - Gene expression of breast cancer related genes in circulating tumour cells (CTCs) from patients with metastatic breast cancer**  
K. Aaltonen, C. Graffman, A.-M. Larsson, L. Rydén; SE
- 17:45 - 17:45 **45P - Cost-effectiveness analysis of VEGF-A testing to predict response to bevacizumab (BEV) as a component of neo-adjuvant therapy of early HER-2 negative breast cancer**  
P. Blank<sup>1</sup>, S. Loibl<sup>2</sup>, B. Linderholm<sup>3</sup>, S. Caramuta<sup>3</sup>, V. Nekljudova<sup>2</sup>, T. Szucs<sup>1</sup>, J. Van Stiphout<sup>1</sup>, Z. Ademi<sup>1</sup>, G. von Minckwitz<sup>2</sup>, M. Schwenkglenks<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>DE, <sup>3</sup>SE
- 17:45 - 17:45 **46P - p53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – A translational subproject of the GeparSixto trial**  
S. Darb-Esfahani, W. Weichert, C. Denkert, G. von Minckwitz, V. Nekljudova, J. Lindner, V. Endris, F. Khandan, S. Loibl; DE
- 17:45 - 17:45 **47P - Defining prognostic and therapeutic selective classes of TNBC**  
E. Knudsen, J. Franco, U. Balaji, A. Witkiewicz; TX/US
- 17:45 - 17:45 **48P - Low hormone receptor (HR) status and the benefit of hormonal therapy (HT) in patients with early breast cancer (EBC)**  
C. Guarducci, M. Bonechi, C. Biagioni, L. Malorni, L. Biganzoli, M.C. Truglia, S. Vitale, G. Soldi, A. Di Leo, I. Migliaccio; IT
- 17:45 - 17:45 **49P - Molecular classification of basal-like breast cancer subtypes based on predictive survival markers**  
H. Milioli, I. Tishchenko, C. Riveros, R. Berretta, P. Moscato; NSW/AU
- 17:45 - 17:45 **50P - Contemporary risk of local, regional and contralateral breast cancer recurrence**  
K. Aalders, A. van Bommel, T. van Dalen, G. Sonke, P. van Diest, L. Boersma, M. van der Heijden - van der Loo; NL
- 17:45 - 17:45 **51P - Pathological complete response (pCR) is not a good marker for inflammatory breast cancer (IBC) patients to predict improved long-term survival after neoadjuvant chemotherapy (NT)**  
F. Fei<sup>1</sup>, L. Tang<sup>2</sup>, G. Di<sup>2</sup>; <sup>1</sup>BE, <sup>2</sup>CN
- 17:45 - 17:45 **52P - A siRNA screen to re-activate senescence in basal-like breast cancer**  
M. Moore, M. Philpott, C. Bishop; UK
- 17:45 - 17:45 **53P - A novel potential prognostic marker SIRT1 on tumor invasion and metastasis, and tumor recurrence in triple negative breast cancer**  
H. Ryu, I.A. Park, H. Kim, Y.Y. Jung; KR
- 17:45 - 17:45 **54P - Differential expression of the protein phosphatase 2 (PP2A) complex and breast cancer signature genes following suppression of mTOR signalling**  
C. Saliba, S. Baldacchino, R. Gauci, M.P. Grixti, V. Petroni, A. Zerafa Simler, N. Mallia, A. Fenech, C. Scerri, G. Grech; MT
- 17:45 - 17:45 **55P - Evaluation of the role of MCPH1 and p53 expression in response to chemotherapy and subsequent survival in breast cancer**  
A. Awaji, A. Shaaban, S. Shukla, J. Bond, E. Morrison, V. Cookson, S. Bell; UK

- 17:45 - 17:45 **56P - Soluble serum Fas as a biomarker of early detection of bone or liver metastases in women with advanced breast cancer. A preliminary case-control study**  
F. Lumachi, G. Lo Re, L. Foltran, R. Tozzoli, G. Chiara, S. Basso; IT
- 17:45 - 17:45 **57P - Somatic BRCA1 mutations determine different responses to platinum-based chemotherapy**  
E. Ignatova, M. Frolova, E. Glazkova, M. Stenina, A. Petrovsky, A. Burdenny, V. Loginov, M. Filippova, L. Lyubchenko, S. Tjulandin; RU
- 17:45 - 17:45 **58P - Concordance of local and central HER2 status in 1597 patients participating in German neoadjuvant breast cancer studies**  
B. Pfitzner, S. Loibl, J. Lindner, P. Sinn, B. Lederer, S. Braun, K. Schmid, C. Denkert, G. von Minckwitz; DE
- 17:45 - 17:45 **59P - C8A, a potential predictive marker of trastuzumab benefit, is associated with immunological signatures in MSigDB**  
S. Willis<sup>1</sup>, B. Young<sup>1</sup>, C. Williams<sup>2</sup>, B. Leyland-Jones<sup>1</sup>; <sup>1</sup>SD/US, <sup>2</sup>US
- 17:45 - 17:45 **60P - AP-2gamma as a novel biomarker of endocrine resistance: Results from the TransCONFIRM study**  
L. Malorni<sup>1</sup>, C. Biagioni<sup>1</sup>, C. Guarducci<sup>1</sup>, M. Bonechi<sup>1</sup>, G. Capaccioli<sup>1</sup>, R. Jeselsohn<sup>2</sup>, W. Barry<sup>2</sup>, N. Laing<sup>2</sup>, A. Di Leo<sup>1</sup>, I. Migliaccio<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>MA/US
- 17:45 - 17:45 **61P - Nectin4 effects in the tumor phenotype**  
A. Ghidouche<sup>1</sup>, L. Marc<sup>2</sup>, R. Castellano<sup>2</sup>, D. Olive<sup>2</sup>; <sup>1</sup>DZ, <sup>2</sup>FR
- 17:45 - 17:45 **62P - A exon polymorphism rs700519 (R264C) at CYP19 gene locus is associated with the efficacy of adjuvant letrozole in Indian breast carcinoma patients**  
G. Umamaheswaran, D. Kadambari, B. Dubashi, S.A. Dkhar; IN
- 17:45 - 17:45 **63P - Expression of cohesin subunit SA2 predicts breast cancer survival**  
H. Repo, FI
- 17:45 - 17:45 **64P - Neoadjuvant chemotherapy in breast cancer patients induces miR-34a expression**  
P. Freres, C. Josse, N. Bovy, M. Boukerroucha, I. Struman, V. Bours, G. Jerusalem; BE
- 17:45 - 17:45 **65P - GIRK1 overexpression correlates with ER positive breast cancer subtypes and is associated with poor prognosis**  
S. Kammerer<sup>1</sup>, A. Sokolowski<sup>1</sup>, H. Hackl<sup>1</sup>, D. Platzer<sup>1</sup>, S. Jahn<sup>1</sup>, F. Peintinger<sup>1</sup>, F. Symmans<sup>2</sup>, W. Schreibmayer<sup>1</sup>, T. Bauernhofer<sup>1</sup>; <sup>1</sup>AT, <sup>2</sup>TX/US
- 17:45 - 17:45 **66P - Histology and molecular characteristics of pregnancy associated breast cancer**  
Z. Tomasevic, Z. Milovanovic, I. Bozovic Spasojevic, Z. Tomasevic, S. Milosevic, Z. Zdrale, N. Andjelic Dekic, Z. Kovac; RS
- 17:45 - 17:45 **67P - The impact of the uPAR system and its interaction partners as potential therapeutic targets in TNBC**  
M. Huber, N. Falkenberg, E. Gross, R. Mall, H. Braselmann, M. Schmitt, M. Aubele; DE
- 17:45 - 17:45 **68P - Prognostic value of periostin (PN) expression in early breast cancer (BCa): Long-term mortality outcomes**  
P.V. Nuzzo, A. Rubagotti, L. Zinoli, S. Salvi, S. Boccardo, F. Boccardo; IT

- 17:45 - 17:45 **69P - Diagnostic and prognostic role of stromal CD 10 and Ki 67 in benign and malignant phylloides tumor of breast: A pilot study**  
S. Kumar, D. Singh, S. Gupta, V. Singh; IN
- 17:45 - 17:45 **70P - Discordance with estrogen receptor alpha status estimated by immunohistochemical and immunofluorescent method associated with flowcytometry in breast cancer tissue**  
M. Rodionova, T. Bogush, E. Dudko, E. Shestakova, E. Bogush, V. Kirsanov, I. Vorotnikov; RU
- 17:45 - 17:45 **71P - Relevance of glycosylation-associated genes for tumor progression and metastasis localization in breast cancer**  
L. Oliveira-Ferrer, T. Karius, I. Witzel, T. Karn, R. Wirtz, V. Müller, K. Milde-Langosch; DE
- 17:45 - 17:45 **72P - Male breast cancer receptor sub-types: Demographics, tumor characteristics and short term survival outcomes**  
S. Yadav, D. Isaac, D. Zakalik; US
- 17:45 - 17:45 **73P - Standardize uptake value of 18F-FDG-PET-CT is in accordance with the 21-gene recurrence score (Oncotype Dx) in ER-positive and HER2-negative breast cancer patients**  
S.G. Ahn, J.-H. Lee, J.T. Park, H.M. Lee, T.J. Jeon, Y.H. Ryu, J. Sohn, M. Yun, J. Jeong; KR
- 17:45 - 17:45 **74P - Infrared imaging: A potential new tool to probe tumor cells and their immune micro-environment in breast cancer?**  
M. Verdonck, S. Garaud, R. de Wind, K. Willard-Gallo, E. Goormaghtigh; BE
- 17:45 - 17:45 **BREAST CANCER HOST IMMUNE AND STROMAL BIOLOGY**
- 17:45 - 17:45 **75P - Chemokine expression drives immune cell infiltration in response to oestrogen-deprivation in a model of oestrogen receptor positive breast cancer**  
A. Dunbier, J. Hazlett, B. Hunter, R. Kemp; NZ
- 17:45 - 17:45 **76P - Tumour infiltrating lymphocytes in inflammatory breast cancer**  
C. Colpaert, M. Marsan, G. Van den Eynden, P. Vermeulen, L. Dirix, S. Van Laere; BE
- 17:45 - 17:45 **77P - CXCL13 and tertiary lymphoid structures formation in the anti-breast cancer immune response**  
E. Migliori, C. Gu-Trantien, S. Garaud, L. Buisseret, H. Duvillier, J.-N. Lodewyckx, L. Van Schoonwinkel, A. Boisson, K. Willard-Gallo; BE
- 17:45 - 17:45 **78P - Evaluation of PDL1 expression in breast cancer by immunohistochemistry**  
C. Solinas, L. Buisseret, S. Garaud, A. Boisson, C. Naveaux, P. De Silva, E. Migliori, R. de Wind, D. Larsimont, K. Willard-Gallo; BE
- 17:45 - 17:45 **79P - Expression of transcription factor FOXP1 in the immune response to breast cancer**  
P. De Silva, S. Garaud, E. Migliori, C. Solinas, A. Boisson, C. Naveaux, S. Pecenko, R. de Wind, D. Larsimont, K. Willard-Gallo; BE
- 17:45 - 17:45 **80P - Stromal protein expression in breast cancer is differentially regulated by TGF- $\beta$ 1**  
M. Van Bockstal, K. Lambein, M. Van Gele, E. De Vlieghere, R. Limame, G. Braems, M. Bracke, H. Denys, L. Libbrecht, O. De Wever; BE
- 17:45 - 17:45 **81P - Expression of the small GTPase Rab27B is associated with stromal inflammation in ductal carcinoma in situ of the breast**  
M. Van Bockstal, K. Lambein, O. De Wever, H. Denys, G. Braems, R. Van den Broecke, V. Cocquyt, M. Bracke, L. Libbrecht, A. Hendrix; BE

17:45 - 17:45 **IMAGING (PRECLINICAL AND CLINICAL)**17:45 - 17:45 **82P - Examination of the sentinel lymph node identification in breast cancer combining contrast-enhanced ultrasonography and the blue dye method without radioisotope**K. Futsuhara, K. Omoto, K. Suzuki, A. Yoshizawa, S. Tamaki, T. Rikiyama; JP17:45 - 17:45 **83P - Repeatability evaluation of PET/CT imaging using [18F]fluorothymidine (FLT) and [18F]fluorodeoxyglucose (FDG) in primary triple negative breast cancer (TNBC)**J. Glendenning, S. Barrington, H. Tovey, J. Parikh, J. Dunn, A. Tutt; UK17:45 - 17:45 **84P - 3D MRI for quantitative analysis of quadrant percent breast density (QPD): Correlation with quadrant location of breast cancer**J.-H. Chen, Y. Li, M.-Y. Su; CA/US17:45 - 17:45 **85P - Location of triple-negative breast cancers: Comparison with estrogen receptor-positive breast cancers on MR imaging**W.K. Moon, KR17:45 - 17:45 **PRECLINICAL BREAST CANCER BIOLOGY**17:45 - 17:45 **87P - Inhibition of triple negative and herceptin-resistant breast cancer proliferation and migration by annexin A2 antibodies**J. Vishwanatha<sup>1</sup>, P. Chaudhary<sup>2</sup>; <sup>1</sup>TX/US, <sup>2</sup>US17:45 - 17:45 **88P - Targeting unique metabolic vulnerabilities in dormant ER+ tumor cells**E. Knudsen, J. Franco, A. Witkiewicz; TX/US17:45 - 17:45 **89P - Relevance of -Gal-GalNAc-containing O-glycans and the enzymes involved in their synthesis for vascular and lymphatic invasion and survival in breast cancer patients**K. Milde-Langosch, L. Oliveira-Ferrer, D. Schütze, H. Wikman, I. Witzel, C. Schröder, K. Pantel, U. Schumacher, V. Müller; DE17:45 - 17:45 **90P - Dual role of endothelial cell signaling in cancer progression**D. Ferraro<sup>1</sup>, R. Goosen<sup>1</sup>, F. Patella<sup>2</sup>, S. Zanivan<sup>2</sup>, M. Buess<sup>1</sup>, G. Christofori<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>UK17:45 - 17:45 **91P - Low spinophilin expression is associated with poor prognosis and cellular growth in human breast cancer**D. Schwarzenbacher, V. Stiegelbauer, A. Deutsch, A. Ress, A. Aigelsreiter, S. Schauer, A. Gerger, G. Höfler, B. Rinner, M. Pichler; AT17:45 - 17:45 **BREAST CANCER TARGET IDENTIFICATION, VALIDATION AND PRECLINICAL MODELS**17:45 - 17:45 **93P - Targeting the hedgehog signalling pathway in triple negative breast cancer**M. Hui, A. Cazet, Y. Jessica, C. Cooper, A. McFarland, R. Nair, S. O'Toole, A. Swarbrick; NSW/AU17:45 - 17:45 **94P - The tyrosine kinase AXL sustains EMT and tumour-associated inflammation in triple-negative breast cancers**C. Raschioni<sup>1</sup>, G. Bottai<sup>1</sup>, B. Szekeley<sup>2</sup>, A. Losurdo<sup>1</sup>, L. Di Tommaso<sup>1</sup>, C. Tinterri<sup>1</sup>, L. Paladini<sup>1</sup>, J. Kulka<sup>2</sup>, M. Roncalli<sup>1</sup>, L. Santarpia<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>HU



- 17:45 - 17:45 **95P - Targeting the ASCT2 glutamine uptake and metabolism pathway in triple-negative breast cancer**  
M. van Geldermalsen<sup>1</sup>, Q. Wang<sup>2</sup>, C.G. Bailey<sup>2</sup>, Y. Feng<sup>2</sup>, R. Nagarajah<sup>2</sup>, A. Marshall<sup>2</sup>, A. Thoeng<sup>2</sup>, S. O'Toole<sup>2</sup>, J.E..J. Rasko<sup>2</sup>, J. Holst<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>NSW/AU
- 17:45 - 17:45 **96P - CD146/Akt/NF-kappa-B/Latexin, a novel pathway suppressing breast tumor growth**  
I. Gupta, A. Ouhtit, A. Fernando, Z. Abd Elmageed, S. Shanmuganathan; OM
- 17:45 - 17:45 **97P - Interleukin-6 expression is involved in the response to HER2-targeted therapy in breast cancer**  
Y.-J. Chen, P.-H. Chien, H.-L. Pan, W.-C. Huang; TW
- 17:45 - 17:45 **98P - Heterogeneous responses of triple negative breast cancer cell lines to radiation and pharmacological treatments**  
X. Xie, B. Wieland, B. Schröder-Heurich, N. Bogdanova, T. Dörk-Bousset; DE
- 17:45 - 17:45 **99P - Consensus on breast cancer cell lines classification for an effective and efficient clinical decision-making**  
H. Milioli, I. Tishchenko, C. Riveros, J. Sakoff, R. Berretta, P. Moscato; NSW/AU
- 17:45 - 17:45 **100P - Molecular cochaperone & its deregulation in breast cancer**  
K.-L. Tan, F. Pezzella; UK
- 17:45 - 17:45 **101P - Smart delivery of lapatinib to reduce its cardiotoxicity: A 99mTc labeled biodistribution study**  
A. Khanna, A. Khanna, N. Gupta, S. Trivedi; IN

**05-08-2015**

- 08:15 - 09:00 Dissecting the proteome of breast cancer** **Gold Hall**  
 Chair: F. Symmans, US; C. Desmedt, BE
- 08:15 - 08:45 **Dissecting the proteome of breast cancer**  
M. Ellis, TX/US
- 08:45 - 09:00 **Q&A**





<b>09:00 - 10:15</b>	<b>Mutations and therapy resistance: Impact of mutations in the clinic</b>	<b>Gold Hall</b>
	Chair: G. Curigliano, IT; M. Ellis, US	
09:00 - 09:15	<b>ESR1 mutations and resistance to endocrine therapy</b> <u>S. Chandarlapaty</u> , NY/US	
09:15 - 09:25	<b>920 - The Breast International Group (BIG) AURORA pilot study for molecular screening in metastatic breast cancer (MBC) patients</b> <u>M. Maetens</u> <sup>1</sup> , A. Irrthum <sup>1</sup> , S. Loibl <sup>2</sup> , J.F. Laes <sup>1</sup> , P. Campbell <sup>3</sup> , P. Aftimos <sup>1</sup> , A. Thompson <sup>4</sup> , J. Cortes Castan <sup>5</sup> , S. Loi <sup>6</sup> , C. Sotiriou <sup>1</sup> ; <sup>1</sup> BE, <sup>2</sup> DE, <sup>3</sup> UK, <sup>4</sup> US, <sup>5</sup> ES, <sup>6</sup> AU	
09:25 - 09:40	<b>Mutations in PIK3CA and ERBB2: resistance mechanism, therapeutic target, or both?</b> <u>L. Krop</u> , US	
09:40 - 09:55	<b>Clinical relevance: How do we manage mutational mechanisms of resistance?</b> <u>S. Loibl</u> , DE	
09:55 - 10:15	<b>Q&amp;A / General Discussion</b>	
<b>10:15 - 10:45</b>	<b>Coffee break</b>	<b>Delvaux Foyer</b>
<b>10:45 - 12:15</b>	<b>Microenvironment and metastatic cascade in breast cancer</b>	<b>Gold Hall</b>
	Chair: K. Willard-Gallo, BE; C. Sotiriou, BE	
10:45 - 11:05	<b>Tumour evolution in the metastatic setting</b> <u>C. Desmedt</u> , BE	
11:05 - 11:25	<b>The impact of tumour genetics on host immune response</b> <u>M. Hellman</u> , NY/US	
11:25 - 11:45	<b>Strategies to modulate the immune system in breast cancer: Checkpoint inhibitors and beyond</b> <u>K. Willard-Gallo</u> , BE	
11:45 - 12:00	<b>Clinical perspectives</b> <u>G. Curigliano</u> , IT	
12:00 - 12:15	<b>Q&amp;A / General Discussion</b>	
<b>13:15 - 14:15</b>	<b>Lunch</b>	<b>Delvaux Foyer</b>



**14:15 - 16:20 Translational clinical trial approaches in early stage breast cancer Gold Hall**  
Chair: A.M. Thompson, US; M. Piccart, BE

14:15 - 14:35 **New aspects of molecular imaging in breast cancer**  
E.G.,E. de Vries, NL

14:35 - 14:55 **If I were to start the I-SPY trials again what would I do differently?**  
L. Essermann, CA/US

14:55 - 15:15 **Selection criteria for post neoadjuvant therapy concepts**  
G. von Minckwitz, DE

15:15 - 15:35 **POETIC strategies: Optimising neo-adjuvant and window studies in oestrogen receptor positive breast cancer**  
M. Dowsett, UK

15:35 - 16:20 **Moderated panel discussion: Integration of neoadjuvant and adjuvant trials – do we need new strategies for early breast cancer?**  
A.M. Thompson, TX/US

**16:20 - 16:40 Coffee break Delvaux Foyer**

**16:40 - 17:40 The impact of germline genetics on breast cancer risk and integration in clinical practice Gold Hall**  
Chair: J. Garber, US; A. Tutt, UK

16:40 - 17:10 **The impact of germline genetics on breast cancer risk and integration in clinical practice**  
N. Rahman, UK

17:10 - 17:30 **Clinical interpretation**  
J. Garber, MD/US

17:30 - 17:40 **Q&A / General Discussion**

*05-09-2015*

**09:00 - 10:00 Chemotherapy will have a trivial role in the future of precision medicine Gold Hall**  
Chair: S. Loibl, DE; F. André, FR

09:00 - 09:20 **Pro**  
G. von Minckwitz, DE

09:20 - 09:40 **Contra**  
L. Norton, NY/US

09:40 - 10:00 **Moderated discussion with audience**  
F. André, FR





10:00 - 10:30	<b>Coffee break</b>	Delvaux Foyer
10:30 - 11:45	<b>Triple negative breast cancer: First results from tackling the diversity</b> Chair: N. Turner, UK; P. Schmid, UK	Gold Hall
10:30 - 10:45	<b>Genomic and morphological heterogeneity in TNBC</b> <u>J. Reis-Filho</u> , NY/US	
10:45 - 11:00	<b>Platinum and targeted therapy in TN breast cancer- for all patients or only a subset?</b> <u>A. Tutt</u> , UK	
11:00 - 11:45	<b>Panel discussion: Potential resistance targets, recent study results and new trial concepts</b> <u>P. Schmid</u> <sup>1</sup> , <u>F. André</u> <sup>2</sup> , <u>I. Krop</u> <sup>3</sup> , <u>J. Reis-Filho</u> <sup>4</sup> , <u>F. Symmans</u> <sup>5</sup> , <u>A. Tutt</u> <sup>1</sup> , <u>N. Turner</u> <sup>1</sup> , <u>G. von Minckwitz</u> <sup>6</sup> ; <sup>1</sup> UK, <sup>2</sup> FR, <sup>3</sup> US, <sup>4</sup> NY/US, <sup>5</sup> TX/US, <sup>6</sup> DE	
10:30 - 10:45	<b>Susan G. Komen for the Cure® award session (TBC)</b>	Gold Hall
11:45 - 12:00	<b>Closing remarks and introduction of the IMPAKT 2016 Chairs</b> Chair: N. Turner, UK; C. Denkert, DE	Gold Hall
11:45 - 12:00	<b>Closing remarks</b> <u>C. Denkert</u> <sup>1</sup> , <u>N. Turner</u> <sup>2</sup> ; <sup>1</sup> DE, <sup>2</sup> UK	